chrisvoncsefalvay/vaers-outcomes huggingface dataset:
cough; sore throat; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (cough) and OROPHARYNGEAL PAIN (sore throat) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COUGH (cough) and OROPHARYNGEAL PAIN (sore throat). At the time of the report, COUGH (cough) and OROPHARYNGEAL PAIN (sore throat) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. No treatment medication was reported.
"Breakout" on 3/8/14 -> went to doctor -> Dx "shingles" all over body. "Feeling bad" on 3/7/14. Date ZOSTAVAX administered on 3/4/14.
Works in a quarry. Kills skunks.  Could smell the skunks even when it sprayed several  time. Loss all sense of smell.  Sense of smell hasn't returned. Slight fever after the shot. Upper nasal passages seem to be  constricting, has increased in severity. Now it is concerning . Does feel like he is getting any better.
Ten minutes after vaccines, father of pt. reported pt. felt lightheaded then went limp and passed out. Doctor immediately went in room and pt. was awake. Blood sugar was checked and normal. Pt. sat up and within ten minutes fell back to normal.
flu-like symptoms; Mainly flu-like symptoms such as chills, body aches, fatigue, headache; Mainly flu-like symptoms such as chills, body aches, fatigue, headache; Mainly flu-like symptoms such as chills, body aches, fatigue, headache; Mainly flu-like symptoms such as chills, body aches, fatigue, headache; Feeling exhausted; Very swollen at injection site with redness; Very swollen at injection site with redness; Enlarged lymph nodes on right axilla with pain in left axilla; Enlarged lymph nodes on right axilla with pain in left axilla; This is a spontaneous report from a contactable Nurse (patient). This 39-year-old female Nurse (no pregnant) received the second dose of BNT162B2 (lot number=EL 1284) Intramuscular on 08Jan2021 05:45 PM on Left arm for covid-19 immunization. Medical history was High Blood Pressure, Depression. Concomitant drug included Labetalol, Lisinopril, bupropion hydrochloride (WELLBUTRIN). Past drug was the first dose of BNT162B2 (lot number=EH9899, vaccine location=Left arm) Intramuscular on 18Dec2020 01:30 PM. Patient experienced Mainly flu-like symptoms such as chills, body aches, fatigue, headache. Feeling exhausted. Very swollen at injection site with redness. Enlarged lymph nodes on right axilla with pain in left axilla on 09Jan2021 01:30 PM. Outcome of the event was recovering. No other vaccine in four weeks. No treatment. No covid prior vaccination. No covid tested post vaccination.  Follow-up attempts are completed. No further information is expected.
arm very sore initially, and very HEAVY, but that passed within 24 -48 hours. However, soreness has now returned to the left arm.
Had pain in LT upper arm since received flu shot. Had shooting pain when vaccine was given. Pain worse when reaching across her body. Persistent pain in mid lateral humerus region.
vertigo; light headedness; nausea; This is a spontaneous report received from a contactable other health professional (patient herself). A 26-year-old female patient (not pregnant) received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection) via an unspecified route of administration on left arm on 19Jan2021 12:15 at single dose for COVID-19 immunisation at hospital. Medical history included depression and anxiety. The patient had no allergies to medications, food, or other products. Concomitant medication included trazodone at 100 mg and sertraline at 150 mg; both are received within two weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. It was reported that, two weeks after vaccine (on 01Feb2021 22:00) the patient had onset of vertigo, light headedness, and nausea. Patient still experiencing vertigo 12 hours later. Did not imbibe alcohol or substances. Did not do strenuous activity. The adverse events result in doctor or other healthcare professional office/clinic visit. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The events were assessed as non-serious by the reporter. The outcome of the events was reported as recovering.  Information on the lot/batch number has been requested.
Vaccine was administered in right arm. Experienced mild pain for about 24 hours; I did experience itching on my lower back, buttocks, and back of both legs for about 36 hours. No rash but a moderate itching sensation; This is a spontaneous report from a contactable consumer (patient). A 64-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection) via unspecified route of administration, administered in arm right on 04Mar2021 at 12:45 (PM) (at the age of 64-year-old) as 1st dose, single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously took flu vaccination (annual flu vaccination) and experienced mild pain. No other vaccine in four weeks and no treatment received. No covid prior vaccination and did not tested covid post vaccination. The patient known allergies were none. The patient got vaccine in right arm and experienced mild pain on an unspecified date Mar2021 (for about 24 hours) similar to that of the annual flu vaccination, itching on his lower back, buttocks, and back of both legs for about 36 hours. No rash but a moderate itching sensation. Outcome of the event was recovered on an unknown date in 2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
I noticed a mild itch at the injection site on May 6th. I do not recall the time. There is a red area about 2-1/2" in diameter. It appears to be "covid arm."  I had not looked at the injection site since the injection, so I do not know if it was red prior to May 6th. I took oral benedryl for one day, but stopped due to the drowsiness. I still have a mild red patch, but no itch as of the time of this report. (9am May 11,2021.)  My vaccine card reads "Moderna 005C21A" next to first dose. My second dose is scheduled for June 1st.
Patient showed picture of big red swollen site with blisters to pharmacy staff on 11/10/23.
6 days after getting shot, I developed rashes on the arm where I got the shot. Very intense inflammation and itchiness. Used a prescription topical ointment and OTC itch relief lotion to relieve the itchiness and inflammation which spread to my torso and also the other arm, but to a lesser degree.  The itchiness subsided so I stopped using the prescription ointment, but after 2-3 days (13 days after I got the 1st doe shot), I developed the rashes, itchiness and inflammation again on the arm where I got the shot.
Patient complained of tongue feeling raw and hot. Status post second vaccine. Was drinking ? bad water? in their car and started to feel sensation on tongue. No noted shortness of breath or swallowing, speech clear patient alert and oriented no noted deficits. Evaluated by the paramedics, signed out against medical advice. Symptoms resolved and taken home with husband in car
Headache; I start bruising very easily; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 36 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 14Jul2021 14:00 (Lot number: EW0173) at the age of 36 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "No" (unspecified if ongoing), notes: No. There were no concomitant medications. The following information was reported: HEADACHE (non-serious) with onset 15Jul2021, outcome "unknown", described as "Headache"; INCREASED TENDENCY TO BRUISE (non-serious) with onset 2021, outcome "unknown", described as "I start bruising very easily". Therapeutic measures were taken as a result of headache, increased tendency to bruise.  Additional information: No vaccinations (within 4 weeks) prior to the first administration date of the suspect vaccine. She took Tylenol and for bruising she just put her heating pad on it. Her husband experienced chills only after receiving the vaccine. Both doses were at 2 o clock in the evening, received both doses one the same shoulder, on her right shoulder. On 09Aug2021 she went a little late because she was scared to take the second one because of what happened with the first one.  No follow-up attempts are possible. No further information is expected.
Pt reports muscle aches at injection sites as well as headache and general malaise, for first 72 hrs. Followed by upper respiratory congestion, sore throat times 1 week. Resolved and recurrent 4 days later to present cough and chest congestion.
Initial reaction day after vaccination - 4/1/2021 site reaction with swelling, erythema, and warmth; generalized reaction - flu-like symptoms - all resolved within a few days.  6/6/2021 - uncertain if related to vaccine - patient reported chest pain as thought he thought he was having a heart attack. Went to hospital. Dx with pulmonary emboli and DVTs. Transferred from (Name) Hospital to (Name) Hospital to ICU. As of 6/7/2021, patient reports he has been moved from the ICU to a regular room, no on oral anticoagulants. Patient has not yet been discharged at the time of report submission.
Received expired vaccine administered >12/ hours post puncture; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received expired vaccine administered >12/ hours post puncture) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Dec-2021 at 8:00 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received expired vaccine administered >12/ hours post puncture). On 14-Dec-2021, EXPIRED PRODUCT ADMINISTERED (Received expired vaccine administered >12/ hours post puncture) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication information was not provided by the reporter.                            Treatment information was not provided by the reporter.   This case was linked to MOD-2021-414692 (Patient Link).
28FEB pt recv vax & devel rash on face, arms, back & legs;2MAR seen in ER-hands & face swollen, T100.7;mom gave DPH @ home;rx @ hosp w/ice pack for hands;3MAR seen by MD UA & blood work WNL;6MAR 2AM h/a, T100, dizzy, sore throat, stiff neck
brought down to normal people level; This is a spontaneous report from a contactable consumer or other non hcp. This consumer reported for 4 patients. This report is for 4th of 4 patients. This consumer reported for a female patient (sister).  A female patient of an unspecified age received bnt162b2 (PFIZER-BIOTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as unknown single dose for covid-19 immunization. It was reported that While reporting on herself she was mentioned details about her sister when speaking about fatigue. She mentioned with the COVID 19 Vaccine with her and her sister it brought them down to normal people level on an unspecified date. Stated they were way up there anyways. The outcome for the even was reported as unknown at the time of this report.  No follow-up attempts are possible. Lot/Batch number cannot be requested. No further information is expected.
No adverse event; Received second primary dose of the Moderna Covid 19 vaccine more than 35 days after the first one; This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second primary dose of the Moderna Covid 19 vaccine more than 35 days after the first one) and NO ADVERSE EVENT (No adverse event) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 076C21A and 038K20A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy, Nickel sensitivity, Drug allergy (Ionamin.), Allergy to metals (White gold) and Allergy to antibiotic (Sulfa Drugs).   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Oct-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Oct-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second primary dose of the Moderna Covid 19 vaccine more than 35 days after the first one). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second primary dose of the Moderna Covid 19 vaccine more than 35 days after the first one) and NO ADVERSE EVENT (No adverse event) outcome was unknown.            No concomitant drug was reported. No Treatment medications were reported   This case was linked to MOD-2022-625024 (Patient Link).
This spontaneous report as received from a Licensed vocational nurse refers to a patient of unknown age and gender. On an unknown date the patient was vaccinated with an improperly stored dose of GARDASIL (incorrect product storage). The patient received either lot # K011562 (expiry date: 08-APR-2017) or K016966 (expiry date: 10-MAY-2017). There were no previous temperature excursions. Temperature was reported to be 34 F and the timeframe was 5 hours. There was no data logger. No symptoms were reported. Outcome was unknown. No product quality complaint was involved. Additional information has been requested.
Discharge Provider: MD Primary Care Provider: MD Admission Date: 6/18/2022 Discharge Date: Jun 21, 2022  PRESENTING PROBLEM: Hypoxia   HOSPITAL COURSE: Patient is a 73-year-old woman with a history of grade 1 diastolic dysfunction, systolic heart failure with most recent ejection fraction of 28%, type 2 diabetes, CKD stage 3, stage III squamous cell carcinoma of the right upper lobe of the lung status post radiation , DVT and PE, seizure disorder, coronary artery disease, hypertension presented to emergency department due to shortness of breath and generalized weakness.  Was admitted to internal medicine service due to acute hypoxic respiratory failure she required 2-4 L of supplemental oxygen via nasal cannula at the time of arrival.  Film array was positive for COVID.  Her hypoxic respiratory failure most likely was secondary to COVID pneumonia.  Chest x-ray showed diffuse interstitial opacity more prominent in the right upper lobe mostly due to fluid overload.  Patient was started on Decadron.  Her symptoms significantly improved and she was able to be weaned off to room air.  She takes 20 mg of Lasix orally every other day at home which was changed to Lasix 20 every day due to fluid overload. overall patient improved significantly and was transferred to a SAR facility. patient's blood sugars were elevated but her last a1c was 7.2% and steroids would not be continued at discharge given her lack of hypoxemia so this degree of hyperglycemia was expected to resolve spontaneously. at the time of discharge patient was in good spirits with no objections to be sent out. she still had a cough and some shortness of breath on exertion. she was 89% with ambulation and was sent with oxygen and instructions for the facility to wean; she was not sent ou ton steroids but her lasix was increased and she was told to discuss this with her PCP as the need for the increased lasix was likely temporary. all questions and concerns addressed, all meds and follow-ups reviewed.
shingles; Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications.  In 2007, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot#, expiration date, dose, dose# and route not specified) for the long-term prevention of shingles and zoster-related conditions.    On an unspecified date, the patient experienced shingles. On an unspecified date, the patient was treated by a physician. As a direct and proximate result of the patient's use of the zoster vaccine live (ZOSTAVAX) vaccine, the patient had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future.    The outcome of the event shingles was not reported. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).
After receiving Covid vaccine I developed an allergy to egg whites. This was confirmed with food allergy testing. Allergy was not present prior to the vaccine.
fever was reported to be 101.2; fatigue; This case was reported by a other health professional via call center representative and described the occurrence of fever in a 56-year-old male patient who received Herpes zoster (Shingrix) (batch number G4HX3, expiry date 13th May 2022) for prophylaxis.   On 9th September 2020, the patient received the 1st dose of Shingrix .5 ml. On 10th September 2020, 1 days after receiving Shingrix, the patient experienced fever and fatigue. On an unknown date, the outcome of the fever and fatigue were unknown.   It was unknown if the reporter considered the fever and fatigue to be related to Shingrix.  Additional details were provided as follows: The patient had fever 101.2 degree F. The reporter consented to follow up.
feels very sick; This case was reported by a consumer via call center representative and described the occurrence of feeling unwell in a female patient who received Flu Seasonal QIV Quebec (FluLaval Tetra 2019-2020 season) for prophylaxis.   On 13th October 2019, the patient received FluLaval Tetra 2019-2020 season. In October 2019, less than a week after receiving FluLaval Tetra 2019-2020 season, the patient experienced feeling unwell. On an unknown date, the outcome of the feeling unwell was recovered/resolved.   It was unknown if the reporter considered the feeling unwell to be related to FluLaval Tetra 2019-2020 season.  Additional details were provided as follows: This case was reported by the reporter for her friend. The age at vaccination was not reported. The patient received a Flulaval vaccination two days ago and felt very sick. The patient stated that the event was resolved. The reporter did not consent to follow-up. No other information was received. This case has been linked to the case US2019187020, reported by same reporter.
patient was 16 and received the moderna vaccine. Patient had no adverse effects reported as of 10/4/2021
I am experiencing severe ringing in the ears (tinnitus) that occured within 24 hours post getting the vaccine. I am still experiencing ringing in the ears and have since made an appointment with my ENT to determine if there are any other possible issues. I never had ringing in the ears prior to the  vaccine.
Child woke the morning, post vax, with area of swelling and erythema over area of inoculation. It measured approximately 5cm in diameter. Benadryl was given in the afternoon of the day following vaccination with rapid resolution of symptoms over about 10 minutes. Pt left office with minimal erythema and swelling.
I  received 2nd series of covid vaccine on Feb 11 @ 1:15 PM  feeling fine until around 09:00 PM feeling fatigue.  Woke up in the  4:00 A.M. due to  body chills, headache, fever, shortness of breath and feeling sick.  Around  8:30 a.m.  I was feeling very sick shortness breath becomes work I felt  chest tightness and pressure  in  my chest.    I am also feeling dizzy  so my son took me to urgent care after evaluation from the urgent care I was referred to go to the emergency room for further evaluation
11/30/99 Pt recv vax around 1 pm. Found unable to move finger on  L hand same day. L hand feels numb. Had Drs visit and Dr was noncommittal relating symptoms to vax. Numbness had decreased markedly since 11/30/99.
At noon patient started screaming. His legs were probably hurting because his eyes wee wide open and seemed to be terrified. Tried to calm him by breast feeding but was not successful. Started child on Motrin. After 1-2 hours of incessant screaming took child to doctor about 1pm and after 10 minutes form arriving child felt asleep but awoke periodically screaming. During doctor/ nurse examination they found bruising on left leg, purple nodule. When applied pressure on needle marks the body jerked his knee as if in pain and would scream. Doctor recommended Tylenol every 4 hours, to keep an eye on fever apply warm compresses on thighs. Told that baby would improve by next day. Today the baby is feverish and whiny, especially by 3 hours after Tylenol dose.
Redness started on the left side of neck, additional rash developed on the right temple, neck and back. Gave Benadryl and resolved
Day 2 after 1st vaccine - headache, chills, extreme fatigue, pain, swelling and inflammation at the site of vaccine   Day 7 itching at the site of vaccination  Day 8 itching, pain, swelling and inflammation at the site of vaccination
5PM temp reached 102 ax despite APAP 9AM;hives began on arms then legs then abd;seen by MD 12:50;hives were gone but reoccurred again in late afternoon;advised father it was pertussis rxn
I was pregnant when I received the flu vaccine. Sixteen days after getting the vaccine my son was stillborn at 36 weeks gestation. There was no reason found to explain his death.
NO adverse event. Vaccine was in a refrigerator that went out of range for 10 minutes on 10/5/22.  Could not get Sanofi to send documentation supporting the use of open IPOL that was out of range for 10 minute period, therefore all vaccines from this lot is invalidated.
Nausea/vomiting with movement of head-3 hours after shot; loss of balance with inability to walk; nausea/vomiting while sitting or attempting to stand-2 days; leg cramps/charlie horses- 3-5 days; general weakness in arms and legs- weeks/current; difficulty with fine motor movements in fingers and weakness in arms and hands-current
covid vaccine breakthrough case  dose 1 4/26/21 017B21A  Moderna dose 2 5/24/21 043B21A  Moderna
This spontaneous report as received from a certified medical assistant refers to a multiple number of patients. The patients were vaccinated with a dose of GARDASIL (Lot # not reported) on an unspecified date. No other co-suspects were reported. No concomitant medications were reported. The medical assistant reported that on an unknown date, the patients had felt faint and lightheaded after receiving GARDASIL. At the time of the report, the patients' outcomes were unknown. Attempts are being made to obtain additional identifying information to distinguish the individual patients mentioned in this report. Additional information will be provided if available. This is one of several reports received from the same source. Additional information has been requested.
Redness and swelling at injection site, fever (100 - 101), muscle aches all over, lasting 3 1/2 - 4 days.